Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory behçet's disease: A case series

Dermatology

Volumn 228, Issue 3, 2014, Pages 211-214

  Vitale, Antonio ^a   Rigante, Donato ^b   Caso, Francesco ^a,c   Brizi, Maria Giuseppina ^a   Galeazzi, Mauro ^a   Costa, Luisa ^d   Franceschini, Rossella ^a   Lucherini, Orso Maria ^a   Cantarini, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Beh et's disease; Canakinumab; Interleukin 1; Uveitis

Indexed keywords

AZATHIOPRINE; CANAKINUMAB; CYCLOSPORIN A; ETANERCEPT; HEPARIN; HLA B51 ANTIGEN; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SERUM AMYLOID A; ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN; DEFLAZACORT; FIBRINOGEN; IMMUNOGLOBULIN G1; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ANKLE ARTHRITIS; APHTHOUS STOMATITIS; ARTHRITIS; ARTICLE; BACTERIAL ENDOCARDITIS; BEHCET DISEASE; CASE REPORT; CHRONIC DAILY HEADACHE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; EYE INFLAMMATION; FEMALE; FOLLICULITIS; FOLLOW UP; GENITAL ULCER; GRANULOMA ANNULARE; HUMAN; IRIDOCYCLITIS; KNEE ARTHRITIS; LABORATORY TEST; MALE; MONOTHERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PRURITUS; PSEUDOFOLLICULITIS; RECURRENT FEVER; RECURRENT INFECTION; REFRACTORY BEHCET DISEASE; REMISSION; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; UVEITIS; WRIST ARTHRITIS; ARTHRALGIA; DIFFUSE PRURITIC URTICARIA; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HEADACHE; LEUKOCYTOSIS; MIDDLE AGED; MIDDLE FRONTAL GYRUS; MOUTH ULCER; PHYSICAL EXAMINATION; RELAPSE; WRIST DISEASE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; RECURRENCE; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902537469     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000358125     Document Type: Article

References (18)

1. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990; 335: 1078-1080
2. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H: The long-Term mortality and morbidity of Behcet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76. (Pubitemid 36139801
3. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G: Evaluation of current therapeutic strategies in Behcet's disease. Clin Rheumatol 2011; 30: 157-163
4. Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C: Infliximab for the treatment of neuro-Behcet's disease: A case series and review of the literature. Arthritis Rheum 2008; 59: 285-290. (Pubitemid 351272967
5. Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M: Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009; 22: 551-555
6. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P: Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007; 51: 191-196. (Pubitemid 46889493
7. Arida A, Fragiadaki K, Giavri E, Sfikakis PP: Anti-TNF agents for Behcet's disease: Analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70
8. Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM: Long-Term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm 2013; 21: 468-474
9. Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R: Successful use of canakinumab in a patient with resistant Behcet's disease. Clin Exp Rheumatol 2012; 30(3 suppl 72): S115
10. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S: Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. Ann Rheum Dis 2012; 71: 1589-1591
11. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA: Resistant Behcet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-286
12. Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A: Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: An open-label pilot study. Ann Rheum Dis 2012; 71: 563-566
13. Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, Yavuz S: Long-Term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 2011; 129: 288-294
14. Rigante D: The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 2012; 11: 348-356
15. Rigante D, Frediani B, Galeazzi M, Cantarini L: From the Mediterranean to the sea of Japan: The transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013; 2013: 485103
16. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549
17. Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A: Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease: Correlations with disease activity and severity. Isr J Med Sci 1995; 31: 345-348
18. Duzgun N, Ayaşlioǧlu E, Tutkak H, Aydintuǧ OT: Cytokine inhibitors: Soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease. Rheumatol Int 2005; 25: 1-5.